Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|EA1183||ECOG-ACRIN||FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-47||NSABP||A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-0129||RTOG||A Phase III Trial of Concurrent Radiation and Chemotherapy (Followed by Surgery for Residual Primary/N2-3 Nodal Disease) for Advanced Head and Neck Carcinomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|10057||ETCTN||A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|WF-20817CD||NCORP-Wake Forest University||Implementation of Smoking Cessation Services Within NCI NCORP Community Sites with Organized Lung Cancer Screening Programs||Cancer Prevention and Control CIRB||Available to Open|
|EA3132||ECOG-ACRIN||Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated; Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)||Adult CIRB - Late Phase Emphasis||Available to Open|
|AEWS1221||COG||Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479; NSC# 750008; IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma||Pediatric CIRB||Available to Open|
|AAML1031||COG||A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239; NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD||Pediatric CIRB||Available to Open|
|A031702||Alliance||Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0286B||GOG||A Randomized Phase II/III Study Of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo As Initial Therapy For Measurable Stage III Or IVA; Stage IVB; or Recurrent Endometrial Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|